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Introduction
“Non-reproducible single occurrences are of no sig-
nificance to science.” Karl Popper
Oestrogen receptor (ER) cycling is a dogma of the
Oestrogen receptor-positive (ER+) breast cancer field
[1], which stood unchallenged for nearly 20 years, until
recent work by our group [2]. Our aim was to build on
the original, highly cited research papers in this field by
applying next-generation sequencing methods to expand
those previous results from a single gene to the rest of
the genome. It sounded like the next logical step, but
we quickly ran into difficulty: no matter what we tried,
we could not reproduce that early work. In the end, we
found ourselves publishing a paper that contradicted,
rather than expanded, the original results.
It is hard to believe that I was the first person who
had failed to reproduce the previous findings. The
underlying problem is that the pressures of modern
research reward those who get there first and offer lit-
tle to encourage people to publish negative results or
even to get it right. These pressures, in turn, distort
the literature. We, therefore, need to change the cul-
ture into one that enables scientists to take the time to
get the right answer – even if it takes multiple attempts
– and to recognise that there is more to great science
than getting there first.
Standing on the shoulders of giants
For nearly 20 years, it was accepted dogma that, once
stimulated, the ER activated its target genes in succes-
sive 90-min ‘on–off’ cycles [1]. That is, until our recent
publication [2]. The papers that first detailed this pro-
cess in 2000 [1] and 2003 [3] currently have over 1000
citations each, yet we could not replicate their key
findings. It would be surprising if no one else had
encountered this replication problem over the past two
decades. However, the real underlying problem here is
that negative results are often not published.
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The ER, a key driver of 70% of breast cancer
tumours, is a nuclear receptor that is usually inactive
in the cytoplasm. Upon activation of the ER by the
hormone estradiol, the protein dimerises and translo-
cates to the nucleus, where it directly binds to its tar-
get genes to activate transcription. What made the ER
special, though, was that in the early 2000s, several
papers reported that, once activated, the ER binds to
its target DNA and then released it in 90-min cycles,
resulting in a tightly timed transcriptional process. In
this way, genes were proposed to be turned on and off
in cycles.
In 2013, I joined the Markowetz lab as a postdoc,
with grand plans to follow up on these studies. The idea
was to expand on what had been demonstrated for a
single gene in these two highly cited papers by combin-
ing it with the latest techniques in whole-genome
sequencing. The project proposal was peer-reviewed,
assessed to be well-designed, and funded by Breast Can-
cer Now. However, I quickly encountered challenges.
Squinting at data
Initial results from my own experiments seemed to
show the occurrence of the same cyclical signal, as pre-
viously reported, but this result could only rarely be
reproduced. My immediate reaction was that this was
most likely due to how I had carried out these experi-
ments. When thousands of scientists had already cited
the previous two reports, it was neither easy nor neces-
sarily the right choice to discount the published data.
Yet, with each attempt to reproduce the results, my
data continued to tell the same story. Months of work
was put into repeating those early experiments, and
although they provided hints of success, they never
delivered what I considered to be a robust result.
The delays had further implications: the computa-
tional biologist with whom I had planned to work with
became impatient in their wait for data that was not
forthcoming. This person found other projects to work
on and then moved on to a new position. The delays in
reproducing a previous result were not just having a neg-
ative impact on my own research but also on the careers
and lives others who were involved in the project.
I worked relentlessly to overcome these challenges.
In trying to make sense of the data we had, we tested
alternative methods to integrate it and to increase the
power of our genome-wide experiments, none of which
conclusively reproduced the reported cycling. These
attempts were not without some success: one of the
methods would go on to be published separately [4].
However, none of these ideas definitively confirmed
the cycling result we were looking for.
From denial to acceptance to problem
solved
Surrounded by data that contradicted what was pub-
lished, I started to accept that ER cycling was possibly
an artefact. When biased by what the literature told us
to look for, we could find it, but when I looked at the
data as a whole, the effect vanished.
And from my efforts, I identified a key issue: no one
routinely controlled their data for the experimental
variability of immunoprecipitation (IP). IP is an
important laboratory method that uses highly specific
antibodies to selectively bind to target molecules to
enable their purification. However, while antibodies
are very specific, the complexity of the steps in IP pro-
tocols leads to various sources of variability in the
final result. The lack of control in each reported ER
ChIP experiment meant that, despite the huge volume
of work published, you could never conclusively know
if the reported changes in ER binding were biologi-
cally relevant or occurred as a result of technical vari-
ability in the experiment.
A breakthrough came from a collaboration with
Michael Guertin at the University of Virginia. Michael
had previously worked on ER binding, and he shared
my concerns about the lack of rigorous controls in the
standard Chromatin Immunoprecipitation (ChIP) with
next-generation DNA sequencing (ChIP-seq) protocol,
a method that uses IP combined with next-generation
DNA sequencing to identify the genomic locations at
which specific proteins bind DNA. We worked
together to develop a robust method with the controls
needed to solve the key variability issue of ChIP. In
just over a year, we had jointly published Parallel-Fac-
tor ChIP-seq (pfChiP-seq) as a method that would
allow us to finally separate the signal from the experi-
mental variation [5].
Self-correcting, but at whose
expense?
One of the ideals of science is that it is self-correcting.
In public engagement talks, I often use the discovery
of a cure for scurvy as an example of how the acquisi-
tion of knowledge is not always a simple journey.
Many an aspirational scientist is aware of James
Lind’s famous experiment in the 18th century, which
led to the discovery of citrus fruit as a cure for scurvy
[6]. However, by the early 20th century, the leading
scientific theory was that scurvy was caused by the
bacterial contamination of food. As a result, the mea-
sures taken to prevent scurvy were changed and
became ineffective [7]. Eventually, research would re-
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establish the knowledge of a cure, but it took decades,
and over that time, many lives were lost to a relatively
curable disease.
What this and many tales like it tell us is that the
scientific narrative is rarely linear. We will not always
come to the correct conclusion on the first, second or
third attempt.
The often-convoluted path that science takes is not
a problem with the method per se. However, we need
to insure against the impact of irreproducible research
on individuals (the ‘human’ impact), particularly when
jobs and livelihoods depend on the ability to replicate
what’s previously reported. I was fortunate that, due
to being in a secure position, I could take my time and
do the research thoroughly with the support of my
peers.
Given the impact that irreproducible research can
have on researchers’ careers, I believe that we need a
more compassionate career path that takes into
account that scientific research does not happen with-
out personal cost: young scientists might need to finan-
cially support their families or be subjected to visas
that are conditional on their studentship. Running out
of time can mean that a student is not awarded a PhD
nor gets to publish that crucial paper.
These challenges are combined with the pressure on
early-career researchers to deliver high-impact results.
The outcome is an environment that pushes people to
get across the line as quickly as possible, while the
incentives to challenge or to reproduce previous stud-
ies are minimal.
The fallacy of sunk costs
We all have a bias to overvalue what we have invested
in, sometimes heavily, because we are tainted by the
emotional investments we accumulate. This is referred
to as the ‘the fallacy of sunk costs’: the more we invest
in something, the harder it becomes to abandon it.
And this bias still holds even when we know that an
alternative can deliver more for less by way of future
investment. After the publication of the pfChIP-seq
method [5], I was especially aware of the risk of fol-
lowing my initial project further. Was I just a gambler
chasing my losses?
The time and money invested in that project had
been significant, and the process had taken its toll on
some of those working on it. I also had several other
projects in the pipeline that were going well and I had
no idea how much push back I would get at peer
review if I were to try and get my results published.
I was fortunate. I knew my funding was secure, mit-
igating some of those risks. But even though I had
absolute confidence in the methods I had developed, I
knew that we had to get it right first time. Where
ChIP-seq experiments often have two replicates, I
included six. Where most ChIP-seq experiments have
two conditions, I had 10 time points. These choices all
came with added cost, building on the ever-increasing
pressure to get a publishable result.
Confirmation Bias
The experience and time that led up to our final exper-
iment paid off. Data analysis enabled us to clearly see
that our controls were stable. The challenge in repro-
ducing ER cycling genome-wide was not due to my
experimental error; it simply was not there in the data.
It would have been much easier to pick the samples
or the data that gave the effect I was looking for, but
in the end, my doubts were justified. The cycling effect
my brain kept seeing – only hinted at in my data –
was just confirmation bias.
The reviewers’ comments are available with the
resulting publication [2] and are well worth reading.
The response to the original submission shows that
one reviewer had experienced the same challenges as I
had had when trying to replicate the reported results.
Our eyes are drawn to seeing patterns, even when they
are not there. When followed up, none of it was signif-
icant.
In all likeliness, my result will not be the final one
in this story. Within the publication, I stated ‘we
would welcome further replication of this study’, and I
still hold by that statement. It is entirely possible that
what I have found in a cell line might be very different
to what occurs in a patient. There is always the possi-
bility that a future technology will lead to a study that
supersedes my own results. This is a humbling reality
that we must accept as scientists but not one that
should limit us.
Reproducibility as a Philosophy
Kirstie Whitaker, a Research Fellow at the Alan Tur-
ing Institute (London, UK), spoke at the Turing
Institute Health Programme Conference in Manch-
ester, in March 2019 [8]. She discussed the current
barriers to reproducible research. Her belief is that
the key problem is not fraud, but instead the pressure
that the culture of science places on the individual.
The risk of embarrassing, high-profile retractions also
prevents data from being published that could correct
the published literature. Such avoidance also enables
researchers to plead ignorance if they have made a
genuine mistake. Meanwhile, the perceived time and
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cost of working reproducibly and its lack of require-
ment for career progression select against, rather than
promote, a culture that supports scientists to work in
this way.
There is a growing acceptance of the points Kirstie
raises as key challenges facing research excellence. The
Royal Society highlighted similar issues as part of their
‘Changing Expectations’ programme, citing the hyper-
competitive research culture and the current narrow
definitions of success as primary drivers for the chal-
lenges I describe [9]. Likewise, the 2014 review by the
Nuffield Council of Bioethics [10] provided consider-
able evidence for these claims, concluding that the cur-
rent culture ‘create[s] incentives for poor quality
research practices, less collaboration and headline
chasing’.
Personal responsibility for reproducible science is
growing, and strong arguments have successfully been
made that it is in one’s own interest to strive for
reproducible data [11]. However, we need more than
this. We need to make reproducing the work of others
a key part of a scientist’s career, and not just some-
thing done in an ad hoc fashion by the privileged few
who can afford it.
The pressure to be novel and first is systemic and
troubling. Despite attempts to correct the distortions
in the evaluation of scientific research [12], the careers
of scientists are still often assessed and rewarded on
the basis on where they publish rather what they pub-
lish. Or as Brian Nosek, Executive Director of the
Center for Open Science (Virginia, USA) concisely
states: ‘Incentives for individual success are focused on
getting it published, not on getting it right’ [13]. A
recent study by Stephanie Hicks [14] showed that
many of the early single-cell RNA-sequencing experi-
ments mistake variability for novel results, with some
studies showing 100% of the results derived from con-
founding factors. Without releasing the pressure on
individuals, the way in which researchers are currently
assessed and incentivised will continue to distort the
published literature. It would be preferable to have the
time to do it right, while simultaneously allowing sci-
entists to be human and make mistakes, instead of
focusing on novelty, being first and publishing in
highly selective journals.
Where next?
Programmes like the reproducibility project for cancer
biology provide part of the answer [15]. By preregister-
ing the experiments, the outcomes – positive or nega-
tive – are always reported. Scientists will be credited
for their work either way, thereby combating the
inherent publication bias within a system that might
promote the one time that an experiment gives a par-
ticular result, rather than all of the unpublished evi-
dence that it does not. While currently limited in
numbers, in the future, these studies should form an
essential part of every scientist’s career.
We need to challenge the culture of ‘first past the
post’ and the pre-eminence given to high-impact jour-
nal publications. Instead, we need to develop a
research culture in which research outcomes are only
seen as being groundbreaking once they have been
independently validated. In such a culture, those who
replicate research findings are seen as being an impor-
tant part of the research process – as important as
those who got there first. In my case, so few had the
time and resources to challenge the established fact
that they simply published the next novel result with-
out ensuring the underlying model was right.
Reproducible science also means greater impact. In
my example, the ER is of interest as a target for sev-
eral key therapeutics used to treat breast cancer [16].
Understanding the mechanism by which it functions
plays a crucial part in our strategies for future inter-
ventions. However, those future outcomes are only as
good as the evidence that we base them on.
Whatever model we come up with, it does not need
to limit the environment that has already led to
promising young scientists producing high-impact
science. We should continue to value their significant
contributions. We are already seeing back-to-back sub-
missions to journals, when by chance, two groups have
found the same answer from two different directions.
In terms of the science, this is a perfect solution,
reproducible and independent. We need to shift to a
scientific culture where this happens more often. And,
rather than fearing ‘being scooped’ – when another sci-
entist through independent research publishes key find-
ings before you – we should see it as something to
embrace and promote.
What I planned to do seemed like a straightfor-
ward next step for the field. It would have been rea-
sonable to assume that the labs who reported cycling
had all the resources to undertake the work them-
selves; in hindsight, one could say that the lack of
follow-up publications should have been a warning
sign. Discussions I have since had at conferences con-
firm that this was exactly the case, with groups strug-
gling to reproduce the results genome-wide.
Nonetheless, none of that insight or those conversa-
tions were possible without the journey I took. In
light of that, the only advice I have for my past self
is: ‘you have to follow the data, even if you don’t
like where it goes’.
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